NCT06718257 Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma
| NCT ID | NCT06718257 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Condition | Cholangiocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2025-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-09-01 with a primary completion date of 2025-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to validate the efficacy and safety of GP/GEMOX combined with PD-1/L1 inhibitors and TKI agents in patients with advanced cholangiocarcinoma through a multicenter, retrospective study to guide clinical practice.
Eligibility Criteria
Inclusion Criteria: * Histologically or radiologically confirmed intrahepatic cholangiocarcinoma * Initially treated with GP/GEMOX or GP/GEMOX combined with PD-1/L1 and TKI inhibitors Exclusion Criteria: * Direct surgery after hospitalization * Initial treatment combined with local therapies (radiotherapy, radiofrequency, particle implantation, TACE, etc.) * Initial treatment involving other comprehensive therapeutic regimens
Contact & Investigator
Weilin Wang, PHD
STUDY CHAIR
Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University
Frequently Asked Questions
Who can join the NCT06718257 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cholangiocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06718257 currently recruiting?
Yes, NCT06718257 is actively recruiting participants. Contact the research team at wam@zju.edu.cn for enrollment information.
Where is the NCT06718257 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06718257 clinical trial?
NCT06718257 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. The principal investigator is Weilin Wang, PHD at Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University. The trial plans to enroll 300 participants.